Patent Application
20170182213
Due to keratitis, keratoconus, other diseases and injuries, a large population in the world today suffers from corneal blindness. However, due to the limited availability of donor corneas especially in developing regions of Asia and Africa, not all individuals can receive treatment.
The following is a briefing of current standards. Existing standards of care include donor corneas, the best cornea replacement currently available. However, there are issues of availability, storage and distribution. Synthetic corneas, or keratoprosthesis such as the Boston Kpro, or AlphaCor also exist in the clinic. However while they can successfully correct for refractive properties of the damaged cornea, they are synthetic polymer based, and do not support tissue remodeling or biointegration, leading to complications. There are bioengineered corneas in clinical trials—such as the carbodiimide crosslinked RHCIII. These show great promise. However, these materials have low suturability and a collagen organizational ultrastructure that does not match that of the cornea (
In the normal collagen assembly seen in the cornea there are a large number of proteoglycans such as decorin and lumican the assist with the triple helix formation, fibril alignment and organization. We wanted to replicate this in the laboratory setting using molecules that can behave as artificial chaperones and can provide these same functions. The inventors' early focus was on cyclodextrins as such molecules (
Cyclodextrins (CDs) are a family of cyclic oligomers composed of a ring of six to eight glucose molecules. These ring molecules feature an inner hydrophobic core and an outer hydrophilic ring that can form complexes with small molecules or portions of large compounds. The solubility of natural cyclodextrins is very poor and initially this prevented cyclodextrins from becoming effective complexing agents. In the late 1960's, it was discovered that chemical substitutions at the 2-, 3-, and 6-hydroxyl sites would greatly increase solubility. The degree of chemical substitution and the nature of the groups used for substitution determine the final maximum concentration of cyclodextrin in an aqueous medium. Most chemically modified cyclodextrins are able to achieve a 50% (w/v) concentration in water. In addition, substitutions and reactions at the hydroxyl groups can provide additional functionality, by, for example, converting the groups to acids, amines, or others. In addition, substitutions and reactions at the hydroxyl groups can provide additional functionality, by, for example, converting the groups to acids, amines, or others.
Extracellular matrix (ECM) is a complex mixture of macromolecules consisting of proteins, proteoglycans, and other soluble molecules. Collagen, the most abundant protein in animals, is widely applied in various bioapplications. However, little effort has been made on engineering an ECM scaffold composed of both collagen and proteoglycans due to difficulty of deriving large amount of purified proteoglycans. In native cornea, the proteoglycans play a critical role in corneal transparency by regulating the collagen fibril diameter and spacing. Therefore, there still exists a need for proteoglycan substitutes to develop biomimetic collagen-based ECM to solve the challenging issues associated with clinical applications, such as corneal regeneration.
In accordance with the disclosed embodiments, the present invention provides compositions and methods for preparing a true corneal mimetic structure. The cornea is a transparent multilayered tissue consists of epithelial and endothelial layers, with the thickest region is the corneal stroma, largely a collagen I based extra cellular matrix, sparsely populated with keratocytes. In some embodiments, one possible strategy is to develop a corneal biomimetic which focuses on replicating the stroma, following which, other layers can be added. This replicated stroma is then used as a base to fabricate collagen based corneal implants which can be tuned to self-assemble into cornea mimetic structures. The goal is to mimic the ultrastructure and physical properties of the native healthy cornea.
In accordance with an embodiment, the present invention provides a composition or membrane that comprises aligned fibrils comprising collagen and cyclodextrin. The composition or membrane may comprise aligned fibrils of a vitrified matrix gel comprising collagen and cyclodextrin.
Aligned fibrils are distinguished from a more random orientation and can be assessed by methods such as transmission electron microscopy evaluation of a sample to detect an aligned orientation rather than a more random configuration.
In the present compositions or membranes, various types of collagen may be suitably employed, including Type I, Type II, Type III and Type IV collagen may be employed. For certain compositions or membranes, Type I collagen can be employed. In certain compositions or membranes, it may be preferred that a substantial portion of the collagen content of the composition is Type I collagen, for example where 40, 50, 60, 70, 8, 90, 95 or 100 weight percent of the total collagen content in the composition or membrane is Type I collagen.
Various cyclodextrins also may be employed, including α-cyclodextrin (α-CD), β-cyclodextrin (β-CD) and γ-cyclodextrin (γ-CD). For certain compositions or membranes, α-CD may be preferred, including in combination with Type I collagen. In certain compositions or membranes, it may be preferred that a substantial portion of the cyclodextrin content of the composition or membrane is α-CD, for example where 40, 50, 60, 70, 8, 90, 95 or 100 weight percent of the total cyclodextrin content in the composition or membrane is α-cyclodextrin (α-CD), including in combination with Type I collagen.
The present compositions or membranes also may comprise one or more additional biologically active or therapeutic agents, such as for example indomethacin.
The present compositions or membranes are especially useful to serve as a drug reservoir to extend the release of drugs to a patient.
The present compositions or membranes also suitably may be multilayered. The composition or membrane may be formed into a variety of configurations including a shape suitable for use as an artificial cornea, and/or a shape suitable for use as a corneal replacement, patch or graft. The present compositions and membranes will have additional uses as a variety of other biological materials.
In accordance with one or more embodiments, the inventors hypothesized that, similar to proteoglycan in native tissues, the incorporation of cyclodextrins in collagen matrix would regulate collagen fibrogenesis while preserving collagen triple helical formation. Traditional engineered type I collagen matrices with fibrillar architectures are opaque, whereas transparent gels composed of amorphous collagen networks exhibit poor mechanical properties. It was expected that cyclodextrins could be added to a collagen matrix as a proteoglycan substitute and would assist in optimizing both optical and mechanical properties for corneal regeneration.
In accordance with an embodiment, the present invention provides a composition comprising a vitrified matrix gel having a first component and a second component, wherein the first component comprises collagen, and wherein the second component comprises cyclodextrin.
In accordance with another embodiment, the present invention provides a composition comprising a vitrified matrix gel having a first component and a second component, wherein the first component comprises collagen, and wherein the second component comprises cyclodextrin, and further comprises at least one biologically active agent.
In accordance with a further embodiment, the present invention provides a method for making a vitrified matrix gel having a first component and a second component, wherein the first component comprises collagen, and wherein the second component comprises cyclodextrin, comprising: a) obtaining an aqueous solution of collagen; b) obtaining an aqueous solution of cyclodextrin; c) combining the solutions of a) and b); and d) dehydrating the combined solution of c) for a period of time sufficient to allow vitrification of the solution.
In accordance with a yet another embodiment, the present invention provides the use of the compositions described above as a matrix for repair of a tissue of a mammal.
In accordance with another embodiment, the present invention provides the use of the compositions described above as a matrix for repair of the cornea of an eye of a mammal.
In accordance with further embodiments, the present invention provides ocular compositions that can be fabricated in layers, with different functionalities per layer to better mimic the cornea.
In accordance with one or more embodiments, the present inventors employed cyclodextrins for use as a proteoglycan substitute to engineer a biomimetic collagen-based matrix composition. The resulting incorporation of cyclodextrin in the inventive collagen compositions increased collagen thermal stability and reduced collagen fibrogenesis. As a result, a thick, transparent and mechanically strong collagen-based composition was formed. These cyclodextrin-collagen compositions hold great potential to be used as a therapeutic eye implants for corneal repair.
In accordance with an embodiment, the present invention provides a composition comprising a vitrified matrix gel having a first component and a second component, wherein the first component comprises collagen, and wherein the second component comprises cyclodextrin.
In accordance with another embodiment, the collagen-cyclodextrin composition can be fashioned into a multilayered or multi-lamellar structure, where thickness of each layer can be controlled. For example, the human cornea is 10-500 micrometers thick. The present invention can be made to thicknesses (micrometers) of 10-500, 25-500; 50-500; 100-500 250-500. The multilayer structure and support multi-functionality, and thus the composition functions more similarly to the cornea than current artificial corneas, grafts or patches. Additionally, the compositions can be coated at the surface to enhance biological action.
In accordance with one or more embodiments of the compositions of the present invention, the inventors used collagen vitrigel technology. Collagen gel vitrification is a slow dehydration process at controlled temperature and controlled humidity that results in formation of collagen membranes or sheets of high transparency and strength. The release of bound water from the collagen results in an increase in entropy driving the formation a high density of fibrils. Vitrification of collagen gels allows the formation of vitrigel membranes with high collagen density, superior strength and higher transparency. (Three steps: Gelation, Vitrification, Rehydration) Previously, CV membranes with higher thicknesses (500 um) had very low transparency (See,
As used herein, the term “vitrification” or “vitrigel” means that the composition is composed of an aqueous solution of a mixture of one or more collagens and one or more cyclodextrins and allowed to form a hydrogel. In some embodiments, the gelation of the composition is performed at a temperature of 37° C. After the hydrogel is formed, the hydrogel is vitrified by dehydration, such as, for example, heating the hydrogel at a specific temperature and humidity, for a specific length of time to allow vitrification to occur. In some embodiments, the vitrification is performed at a temperature of 35 to 45° C. and a humidity of between about 30% and 50% relative humidity. In an embodiment, the vitrification is performed at a temperature of 40° C. and a relative humidity of 40%. The time needed for vitrification of the compositions can vary from a few days to a few weeks. In an embodiment, the time for vitrification of the compositions is about 1 to 2 weeks.
“Gel” refers to a state of matter between liquid and solid, and is generally defined as a cross-linked polymer network swollen in a liquid medium. Typically, a gel is a two-phase colloidal dispersion containing both solid and liquid, wherein the amount of solid is greater than that in the two-phase colloidal dispersion referred to as a “sol.” As such, a “gel” has some of the properties of a liquid (i.e., the shape is resilient and deformable) and some of the properties of a solid (i.e., the shape is discrete enough to maintain three dimensions on a two-dimensional surface).
By “hydrogel” is meant a water-swellable polymeric matrix that can absorb water to form elastic gels, wherein “matrices” are three-dimensional networks of macromolecules held together by covalent or noncovalent crosslinks. On placement in an aqueous environment, dry hydrogels swell by the acquisition of liquid therein to the extent allowed by the degree of cross-linking.
The compositions of the present invention comprise collagen. The collagen of the first component is selected from the group consisting of Type I, Type II, Type III and Type IV collagen. In an embodiment, the collagen used as the first component of the composition is Type I collagen. One of ordinary skill in the art would understand that the collagen used in the compositions and methods could include more than one type of collagen.
The compositions of the present invention also comprise cyclodextrins. The cyclodextrin of the second component is selected from the group consisting selected from the group consisting of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin. In an embodiment, the cyclodextrin used as the second component of the composition is α-cyclodextrin. One of ordinary skill in the art would understand that the cyclodextrin used in the compositions and methods could include more than one type of cyclodextrin.
In accordance with one or more embodiments, the cyclodextrins used in the inventive compositions and methods have a plurality of hydroxyl groups capable of being chemically substituted with another functional group or moiety. Examples of such functional groups or moieties include, but are not limited to, hydrophobic groups, hydrophilic groups, peptides, hydroxyl groups, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkylamino, di-C1-C6 alkylamino, C1-C6 dialkylamino C1-C6 alkyl, C1-C6 thioalkyl, C2-C6 thioalkenyl, C2-C6 thioalkynyl, C6-C22 aryloxy, C2-C6 acyloxy, C2-C6 thioacyl, C1-C6 amido, C1-C6 sulphonamido, C1-C6 carboxyl and derivatives thereof, and also can include phosphonates and sulfones.
As used herein, the vitrified compositions of the present invention are hydrated prior to use.
The vitrigel compositions of the present invention are optically transparent and suitable for a variety of uses. In one embodiment the vitrigel composition has an optical transparency of about 96% at 550 nm.
It will be understood that the vitrigel compositions of the present invention can be molded or formed into any particular shape suitable for use as a replacement tissue or tissue filler. The instant invention provides for ex vivo polymerization techniques to form scaffolds and so on that can be molded to take the desired shape of a tissue defect, promote tissue development by stimulating native cell repair, and can be potentially implanted by minimally invasive injection.
In one or more embodiments, the vitrigel compositions of the present invention can be shaped for use as an artificial cornea for a subject.
In accordance with another embodiment, the present invention provides a composition comprising a vitrified matrix gel having a first component and a second component, wherein the first component comprises collagen, and wherein the second component comprises cyclodextrin, and further comprises at least one biologically active agent.
An “active agent” and a “biologically active agent” are used interchangeably herein to refer to a chemical or biological compound that induces a desired pharmacological and/or physiological effect, wherein the effect may be prophylactic or therapeutic. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of those active agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, analogs and the like. When the terms “active agent,” “pharmacologically active agent” and “drug” are used, then, it is to be understood that the invention includes the active agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, metabolites, analogs etc.
Incorporated,” “encapsulated,” and “entrapped” are art-recognized when used in reference to a therapeutic agent, dye, or other material and a polymeric composition, such as a composition of the present invention. In certain embodiments, these terms include incorporating, formulating or otherwise including such agent into a composition that allows for sustained release of such agent in the desired application. The terms may contemplate any manner by which a therapeutic agent or other material is incorporated into a matrix, including, for example, distributed throughout the matrix, appended to the surface of the matrix (by intercalation or other binding interactions), encapsulated inside the matrix, etc. The term “co-incorporation” or “co-encapsulation” refers to the incorporation of a therapeutic agent or other material and at least one other therapeutic agent or other material in a subject composition.
In one aspect of this invention, a composition comprising a vitrigel composition and one or more biologically active agents may be prepared. The biologically active agent may vary widely with the intended purpose for the composition. The term active is art-recognized and refers to any moiety that is a biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a subject. Examples of biologically active agents, that may be referred to as “drugs”, are described in well-known literature references such as the Merck Index, the Physicians' Desk Reference, and The Pharmacological Basis of Therapeutics, and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. Various forms of a biologically active agent may be used which are capable of being released by the vitrigel composition, for example, into adjacent tissues or fluids upon administration to a subject. In some embodiments, a biologically active agent may be used to, for example, treat, ameliorate, inhibit, or prevent a disease or symptom, in conjunction with, for example, the eye.
Non-limiting examples of biologically active agents include following: adrenergic blocking agents, anabolic agents, androgenic steroids, anti-allergenic materials, anti-cholinergics and sympathomimetics, anti-hypertensive agents, anti-infective agents, anti-inflammatory agents such as steroids, non-steroidal anti-inflammatory agents (NSAIDS), anti-pyretic and analgesic agents, antihistamines, biologicals, decongestants, diagnostic agents, estrogens, ion exchange resins, mitotics, mucolytic agents, growth factors, neuromuscular drugs, nutritional substances, peripheral vasodilators, progestational agents, prostaglandins, vitamins, antigenic materials, and prodrugs.
Examples of NSAIDS used in the compositions of the present invention can include mefenamic acid, aspirin, Diflunisal, Salsalate, Ibuprofen, Naproxen, Fenoprofen, Ketoprofen, Deacketoprofen, Flurbiprofen, Oxaprozin, Loxoprofen, Indomethacin, Sulindac, Etodolac, Ketorolac, Diclofenac, Nabumetone, Piroxicam, Meloxicam, Tenoxicam, Droxicam, Lornoxicam, Isoxicam, Meclofenamic acid, Flufenamic acid, Tolfenamic acid, elecoxib, Rofecoxib, Valdecoxib, Parecoxib, Lumiracoxib, Etoricoxib, Firocoxib, Sulphonanilides, Nimesulide, Niflumic acid, and Licofelone.
Various forms of the biologically active agents may be used. These include, without limitation, such forms as uncharged molecules, molecular complexes, salts, ethers, esters, amides, prodrug forms and the like, which are biologically activated when implanted, injected or otherwise placed into a subject.
The vitrigel compositions will be formulated, dosed and administered in a manner consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The “therapeutically effective amount” of the vitrigel compositions to be administered will be governed by such considerations, and can be the minimum amount necessary to prevent, ameliorate or treat a disorder of interest. As used herein, the term “effective amount” is an equivalent phrase refers to the amount of a therapy (e.g., a prophylactic or therapeutic agent), which is sufficient to reduce the severity and/or duration of a disease, ameliorate one or more symptoms thereof, prevent the advancement of a disease or cause regression of a disease, or which is sufficient to result in the prevention of the development, recurrence, onset, or progression of a disease or one or more symptoms thereof, or enhance or improve the prophylactic and/or therapeutic effect(s) of another therapy (e.g., another therapeutic agent) useful for treating a disease.
In one embodiment, the repair of damaged tissue may be carried out within the context of any standard surgical process allowing access to and repair of the tissue, including open surgery and laparoscopic techniques. Once the damaged tissue is accessed, a vitrigel composition of the invention is placed in contact with the damaged tissue along with any surgically acceptable patch or implant, if needed.
In accordance with a further embodiment, the present invention provides a method for making a vitrified matrix gel having a first component and a second component, wherein the first component comprises collagen, and wherein the second component comprises cyclodextrin, comprising: a) obtaining an aqueous solution of collagen; b) obtaining an aqueous solution of cyclodextrin; c) combining the solutions of a) and b); and d) dehydrating the combined solution of c) for a period of time sufficient to allow vitrification of the solution.
As used herein, the aqueous solution of collagen is any collagen solution dissolved in a suitable buffer. The concentration of the collagen is variable, however solutions of collagen with a concentration in a range of 1 mg/ml to about 10 mg/ml can be used with the methods of the present invention. In an embodiment, the concentration of collagen in aqueous solution is about 5 mg/ml.
As used herein, the aqueous solution of cyclodextrin is any cyclodextrin solution dissolved in a suitable buffer. The concentration of the cyclodextrin is variable, however solutions of cyclodextrin with a concentration in a range of 2.5 mg/ml to about 10 mg/ml can be used with the methods of the present invention.
In accordance with the inventive methods the dehydration and vitrification of the composition of the present invention comprises drying the solution comprising the collagen solution and cyclodextrin at a temperature of about 5 to 40° C., at a relative humidity of between about 30 to 50%, and for a time of about 3 days to about 28 days. In an embodiment, vitrification of the composition of the present invention comprises heating the solution comprising the collagen solution and cyclodextrin at a temperature of 39° C. for about 7 days. In another embodiment, vitrification of the composition of the present invention comprises heating the solution comprising the collagen solution and cyclodextrin at a temperature of 39° C. for about 14 days.
The term, “carrier,” refers to a diluent, adjuvant, excipient or vehicle with which the therapeutic is supplied with the vitrigel composition of the present invention. Such physiological carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a suitable carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions also can be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
Buffers, acids and bases may be incorporated in the compositions to adjust pH. Agents to increase the diffusion distance of agents released from the composition may also be included.
Buffering agents help to maintain the pH in the range which approximates physiological conditions. Buffers are preferably present at a concentration ranging from about 2 mM to about 50 mM. Suitable buffering agents for use with the instant invention include both organic and inorganic acids, and salts thereof, such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture etc.), succinate buffers (e.g., succinic acid monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture etc.), gluconate buffers (e.g., gluconic acid-sodium glyconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture etc.), oxalate buffers (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture etc.) and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture etc.). Phosphate buffers, carbonate buffers, histidine buffers, trimethylamine salts, such as Tris, HEPES and other such known buffers can be used.
Preservatives may be added to retard microbial growth, and may be added in amounts ranging from 0.2%-1% (w/v). Suitable preservatives for use with the present invention include phenol, benzyl alcohol, m-cresol, octadecyldimethylbenzyl ammonium chloride, benzyaconium halides (e.g., chloride, bromide and iodide), hexamethonium chloride, alkyl parabens, such as, methyl or propyl paraben, catechol, resorcinol, cyclohexanol and 3-pentanol.
Isotonicifiers are present to ensure physiological isotonicity of liquid compositions of the instant invention and include polhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol. Polyhydric alcohols can be present in an amount of between about 0.1% to about 25%, by weight, preferably 1% to 5% taking into account the relative amounts of the other ingredients.
The formulations to be used for in vivo administration must be sterile. That can be accomplished, for example, by filtration through sterile filtration membranes. For example, the formulations of the present invention may be sterilized by filtration.
In accordance with one or more embodiments, there is provided ophthalmic formulations comprising the compositions of the present invention, wherein the formulation is suitable for administration to the eye of a subject. The ophthalmic formulation may have a pH between 5.5 and 7. In some embodiments the ophthalmic formulation is an aqueous formulation. In some embodiments the ophthalmic formulation is in the form of a single dose unit. In some embodiments the ophthalmic formulation does not comprise a preservative. The ophthalmic formulation may further comprise one or more additional therapeutic agents, such as antioxidants. The ophthalmic formulation may further comprise one or more tear substitutes. In some embodiments, at least one of the tear substitutes contains an ophthalmic lubricant (e.g., hydroxypropylmethylcellulose).
A variety of tear substitutes are known in the art and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, and ethylene glycol; polymeric polyols such as polyethylene glycol; cellulose esters such hydroxypropylmethyl cellulose, carboxy methylcellulose sodium and hydroxy propylcellulose; dextrans such as dextran 70; water soluble proteins such as gelatin; vinyl polymers, such as polyvinyl alcohol, polyvinylpyrrolidone, and povidone; and carbomers, such as carbomer 934P, carbomer 941, carbomer 940 and carbomer 974P. Many such tear substitutes are commercially available, which include, but are not limited to cellulose esters such as Bion Tears®, Celluvisc®, Genteal®, OccuCoat®, Refresh®, Teargen II®, Tears Naturale®, Tears Natural II®, Tears Naturale Free®, and TheraTears®; and polyvinyl alcohols such as Akwa Tears®, HypoTears®, Moisture Eyes®, Murine Lubricating®, and Visine Tears®. Tear substitutes may also be comprised of paraffins, such as the commercially available Lacri-Lube® ointments. Other commercially available ointments that are used as tear substitutes include Lubrifresh PM®, Moisture Eyes PM® and Refresh PM®. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.
Type I collagen-based membranes incorporated with different cyclodextrins were prepared following a three-stage sequence: gelation, vitrification and rehydration. Three types of cyclodextrins were tested and compared, i.e. α-CD, β-CD and γ-CD.
Preparation of CD solutions: All solutions with various CDs (e.g., α, β and functional groups, COOH, t-butyl, SH, NH2) were prepared in a procedure as described here: For example, a β-CD solution (2.5 mg/mL) in dH2O with 20 nM HEPES (1 mL HEPES, 49 mL H2O and 125 mg β-CD in a 50 ml falcon tube) was added and vortexed thoroughly to dissolve completely. Subsequently, the pH of this solution was increased 11 using a sodium hydroxide (2N) solution, filtered through a 0.22 μm syringe filter and stored at 1-4° C.
Preparation of β-CD Collagen gel: Various gels of collagen and CDs were prepared in a procedure as described here: For example, an equal volume of a β-CD solution (2.5 mg/mL and as prepared above) and a collagen acetic acid solution (5 mg/mL) were mixed together and kept at 4° C. or lower throughout the preparation. Special care was taken to prevent air bubbles formation due to mixing. Then after, the mixture was transferred into gel molds and kept at 37° C. 100% RH incubator for 2 hours.
Vitrification and post-processing of β-CD Collagen: Following 2 hour incubation at 37° C., gels were transferred to 5° C. (40% RH) vitrification chamber for 18 hours. Next, gels were transferred to 40° C. vitrification chamber (40% RH) for one week. After a week, dehydrated β-CD Collagen membranes (vitrigels) were rehydrated in dH2O for 30 minutes. If needed, vitrigels were crosslinked using 0.1% EDAC and 0.1% NHS in dH2O for 30 min in 37° C., washed vitrigels using dH2O at least five times to remove traces of EDAC and NHS. The hydrophilic functional groups induce lamella structures as shown in
Two collagen membranes, i.e. collagen vitrigel and crosslinked vitrigel, were prepared as controls following the procedures as previously described (Biomaterials 34 (2013) 9365-9372). Compared to normal vitrigel, the crosslinked vitrigel was fabricated with additional 0.6% 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 0.6% N-hydroxysuccinimide (NHS) in the collagen media mixture before the gelation process. The specific interactions between collagen and CD were evaluated using differential scanning calorimetry (DSC, Perkin Elmer, Waltham, Mass.). Absorbance of CD-col membranes was measured using a Synergy 2 microplate reader (BioTek, Winooski, Vt.). Membrane suturability was tested with a 10-0 nylon suture using an Electroforce 3200 testing instrument (Bose, Eden Prairie, Minn.).
Keratocytes were isolated from full-thickness corneas using a sequential collagenase (Type 2, Worthington Biochemical Corp., Lakewood, N.J.) digestion. The digested cells were collected and centrifuged at 1400 rpm for 10 minutes. The cell pellet was resuspended and cultured on general tissue culture plates (TCP) or CV-covered plates at 37° C. and 5% CO2. Either serum-free or serum based culture medium was used. The serum-free medium consisted of DMEM/F-12, 1% of 10 U/mL penicillin-streptomycin, and 0.5% of 1.25 mg/mL amphotericin B (Life Technologies, Carlsbad, Calif.). The serum-based medium contained DMEM/F-12, 10% FBS, 1% of 10 U/mL penicillin-streptomycin, and 0.5% of 1.25 mg/mL amphotericin B. The cells were plated at a concentration of 5000 cells/cm2 using the serum-free medium, while at a concentration of 1000 cells/cm2 using the serum-based medium. Before imaging and gene expression analyses, keratocytes were cultured over 3 wk in serum-free medium or 6 d in serum-based medium. Keratocyte morphologies were examined by staining with the LIVE/DEAD® Viability/Cytotoxicity Kit (Life Technologies). Indomethacin was encapsulated in the vitrigels by soaking the vitrified membranes in 0.1% indomethacin eye drops for a period of time. The elution of indomethacin from the vitrigel was measured using high-performance liquid chromatography (HPLC). The release solution was tested using a mobile phase of acetonitrile: water of 51:49 (v/v), a C18 column and a UV/VIS detector set at 318 nm.
All three cyclodextrins, especially α-CD, exhibited strong interactions with type I collagen triple helices, leading to formation of transparent and mechanically strong CD-col membranes. As shown in
Compared to conventional collagen membrane, the CD-col membranes showed greatly enhanced transparency (
Type I collagen-CD membranes were developed with optimized optical and mechanical properties for corneal regeneration. CDs represent a ring of six to eight glucose molecules with an inner hydrophobic core and an outer hydrophilic ring. All three CDs, especially α-CD, exhibited strong interactions with collagen triple helices, leading to formation of mechanically strong collagen-CD membranes. The collagen-CD membranes showed significantly higher transparency than conventional collagen membranes, which can be explained by the greatly reduced the collagen fibril diameter in collagen-CD membranes (˜20 nm) compared to conventional collagen membranes (˜80 nm). Furthermore, unlike conventional collagen membrane exhibiting a random fibrillar organization, the collagen-CD membranes demonstrated aligned fibrils in some regions probably due to reorganization of collagen triple helices by CD. In addition, it was found that the collagen-CD membrane could absorb the ophthalmic drug, indomethacin, from eye drops and then slowly release the drug up to five hours.
The incorporation of cyclodextrin in type I collagen membranes regulated collagen fibrillogenesis and alignment and improved optical, mechanical and drug release properties in membranes.
The inventive compositions demonstrated superior mechanical properties. When their thickness was comparable to that of human cornea (i.e. ˜500 μm), they became strong enough for suture. As shown in
Collagen nanoarchitecture defines cell response. Primary cultures of bovine keratocytes were cultured on vitrigel compositions having low and high collagen density. As shown in
Keratocyte gene expression is dependent on fibril architecture. Keratocytes were cultured on control vitrigels or with the inventive vitrigel compositions where the vitrigels were dehydrated at 5° C. or 39° C. temperatures. After growth for 6 days in serum-based medium, the cells were harvested and analyzed for gene expression of keratocan, aldehyde dehydrogenase (ALDH) and biglycan. The expression of these genes was analyzed by isolating total RNA from cultured keratocytes using TRIzol reagent (Life Technologies), reverse transcribing into cDNA using SuperScript II First Strand Synthesis Kit (Life Technologies) and then testing the cDNA using real-time PCR reactions on a StepOnePlus Real-Time PCR System (Applied Biosystems®, Life Technologies). As shown in
The vitrigel compostions of the present invention can be used to deliver biologically active agents. The vitrigel compositions were prepare as above, and a solution of a commercially available eye drop formulation of 0.1% indomethacin in ethanol was added to the composition for either 10 minutes using two drops or overnight soaking in 1 mL eye drop after hydrating the vitrigels, and the release kinetics were tested using HPLC. It was found that the vitrigel composition released the indomethacin from the vitrigel composition over a 5 hour period.
Type I collagen-CD compositions of the present invention were developed with optimized optical and mechanical properties for corneal regeneration. While not being limited to any particular theory, these properties are probably due to regulated collagen fibrillogenesis in the cyclodextrin-incorporated collagen compositions (
The effect of the interaction of collagen with cyclodextrins on collagen fibrillar organization was studied. Collagen type I in an acidic solution is combined with cyclodextrins solutions of varying compositions. This solution can then be buffered to raise the pH to form gels. These gels are then vitrified over a 1 week period, following which the dry sheets of CD-Col were rehydrated. A variety of sample characterizations were carried out to match the requirements of such an implant in the clinic.
Material was prepared as follows: hydrogel was formed using collagen type I and cyclodextrin solutions in appropriate buffer. The vitrification process was at controlled temperature and relative humidity over a 1 week period. Cyclodextrin collagen vitrigel implants were rehydrated.
Samples required the following clinical properties/tests: light transmittance; transmission electron microscopy; mechanical testing; in vitro biocompatibility studies; preliminary in vivo studies.
These prepared cyclodextrin/collagen materials, even at thickness of 500 microns were clear, especially when compared to the traditional vitrigels without cyclodextrin. Further, it was observed that depending on the type and functional group of the cyclodextrin, variations in transparency were seen. Most of these implants showed transparencies comparable to human corneas, namely above 90% in the visible light range. Interestingly, it was also observed that these thick sheets could, with sufficient force, be separated layer by layer into thinner sheets (See,
Particularly fascinating was the CDs with COOH functional groups, which exhibited self assembled lamellae similar to the lamellae of native corneal stroma (See,
A pilot study was undertaken by implanting these corneas into the rabbit eyes. Regular interrupt sutures were able to hold the material well (
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
This application claims the benefit of International Patent Application No. PCT/US2015/027503, filed Apr. 24, 2015, and U.S. Provisional Patent Application No. 62/156,833, filed on May 4, 2015, both of which are hereby incorporated by reference for all purposes as if fully set forth herein.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2015/049371 | 9/10/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62156833 | May 2015 | US | |
| 61984328 | Apr 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2015/027503 | Apr 2015 | US |
| Child | 15306146 | US |
